0001209191-19-016822.txt : 20190305 0001209191-19-016822.hdr.sgml : 20190305 20190305174711 ACCESSION NUMBER: 0001209191-19-016822 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190301 FILED AS OF DATE: 20190305 DATE AS OF CHANGE: 20190305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Crowley John F CENTRAL INDEX KEY: 0001400973 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 19659939 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-01 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001400973 Crowley John F C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ 08512 1 1 0 0 Chairman & CEO Common Stock 2019-03-01 4 M 0 10763 3.19 A 678844 D Common Stock 2019-03-01 4 M 0 8770 3.82 A 687614 D Common Stock 2019-03-01 4 M 0 467 6.45 A 688081 D Common Stock 2019-03-01 4 S 0 4618 12.9706 D 683463 D Common Stock 2019-03-01 4 S 0 15382 13.7876 D 668081 D Common Stock 64895 I By Trust Stock Options (right to buy) 3.19 2019-03-01 4 M 0 10763 0.00 D 2024-01-03 Common Stock 10763 10209 D Stock Options (right to buy) 3.82 2019-03-01 4 M 0 8770 0.00 D 2024-06-26 Common Stock 8770 0 D Stock Options (right to buy) 6.45 2019-03-01 4 M 0 467 0.00 D 2022-02-15 Common Stock 467 0 D The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $13.31. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.38 to $13.99. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of March 1, 2019 The options exercised in the transaction represent approximately 1.08% of Mr. Crowley's ownership at the time of the transaction. Mr. Crowley intends to exercise his options on a monthly basis. /s/Carol Welch, Attorney-In-Fact 2019-03-05